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Abstract
Background: Food anaphylaxis is commonly elicited by unintentional ingestion of foods 
containing the allergen above the tolerance threshold level of the individual. While 
labeling the 14 main allergens used as ingredients in food products is mandatory in 
the EU, there is no legal definition of declaring potential contaminants. Precautionary 
allergen labeling such as “may contain traces of” is often used. However, this is unsat-
isfactory for consumers as they get no information if the contamination is below their 
personal threshold. In discussions with the food industry and technologists, it was 
suggested to use a voluntary declaration indicating that all declared contaminants are 
below a threshold of 0.5 mg protein per 100 g of food. This concentration is known to 
be below the threshold of most patients, and it can be technically guaranteed in most 
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1  |  INTRODUC TION
Allergic reactions to foods are a major health problem that has in-
creased in prevalence in recent years and affects 5%– 10% of the pop-
ulation in industrialized countries.1 In children and adolescents, food 
allergy is common and considerably impacts the quality of life in these 
patients, as well as their families and caretakers.2 In this age group, 
food allergens are also most commonly the cause of anaphylaxis, 
the most severe form of an allergic reaction. Although fatalities are 
rare, these reactions to food allergens are potentially life- threatening. 
Anaphylaxis elicited by food allergens is most commonly reported 
after unintentional ingestion of foods containing the relevant allergen.
While labeling food products with the 14 main allergens is man-
datory in the EU, precautionary allergen labeling such as “may con-
tain,” “may contain traces of” or “manufactured in a setting where 
‘allergen’ is processed” is voluntarily placed by food manufactur-
ers. The inconsistent food labeling approaches are met with the 
uncertainty of consumers, among whose knowledge about the reg-
ulations and meaning of this labeling is largely missing.3 It also has 
implications for the manufacturers since consumers with a history 
of severe allergic reactions are less likely to buy food products with 
the current precautionary allergen label even though other products 
without precautionary labeling may contain the allergen in the same 
quantities and the same likelihood as the labeled product.3
The implementation of concentrations over which food aller-
gen traces should be declared on the package would therefore 
be helpful for consumers as well as for manufacturers. The major 
problem is that the threshold for elicitation of allergic reactions 
against foods is different in different individuals. The vast majority 
of food allergic patients have no problems with contaminants and 
traces of the relevant allergen. For example, most pollen allergic 
patients with oral food allergy syndrome often only react to the 
pure cross- reacting food allergens if they are present in amounts 
above 1000 mg. On the other hand, there are some severely 
food production. However, it was also important to assess that in case of accidental 
ingestion of contaminants below this threshold by highly allergic patients, no fatal 
anaphylactic reaction could occur. Therefore, we performed a systematic review to 
assess whether a fatal reaction to 5mg of protein or less has been reported, assuming 
that a maximum portion size of 1kg of a processed food exceeds any meal and thus 
gives a sufficient safety margin.
Methods: MEDLINE and EMBASE were searched until 24 January 2021 for provo-
cation studies and case reports in which one of the 14 major food allergens was re-
ported to elicit fatal or life- threatening anaphylactic reactions and assessed if these 
occurred below the ingestion of 5mg of protein. A Delphi process was performed to 
obtain an expert consensus on the results.
Results: In the 210 studies included, in our search, no reports of fatal anaphylactic 
reactions reported below 5 mg protein ingested were identified. However, in provo-
cation studies and case reports, severe reactions below 5 mg were reported for the 
following allergens: eggs, fish, lupin, milk, nuts, peanuts, soy, and sesame seeds.
Conclusion: Based on the literature studied for this review, it can be stated that cross- 
contamination of the 14 major food allergens below 0.5 mg/100 g is likely not to en-
danger most food allergic patients when a standard portion of food is consumed. We 
propose to use the statement “this product contains the named allergens in the list of 
ingredients, it may contain traces of other contaminations (to be named, e.g. nut) at 
concentrations less than 0.5 mg per 100 g of this product” for a voluntary declaration 
on processed food packages. This level of avoidance of cross- contaminations can be 
achieved technically for most processed foods, and the statement would be a clear 
and helpful message to the consumers. However, it is clearly acknowledged that a 
voluntary declaration is only a first step to a legally binding solution. For this, further 
research on threshold levels is encouraged.
K E Y W O R D S
anaphylaxis, food allergy, nutrition
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affected food allergy sufferers, especially to peanuts with thresh-
olds below 1mg. In addition, a true no observed adverse events 
level (NOAEL), as in cosmetic allergy, is not known for food al-
lergens. In summary, this situation is unsatisfactory: overcautious 
reporting of potential contamination of allergens creates unnec-
essary fears in most food allergy sufferers and is not helpful. On 
the other hand, underreporting of potential contamination is en-
dangering those severely affected by food allergies reacting to 
minimal amounts.
As this problem is internationally recognized, some national 
authorities have implemented threshold values over which food 
allergens have to be labeled on the package. Japanese authorities 
have decided on a threshold value based on the precision of ELISA 
test kits.4 As precision parameters of medical measurement equip-
ment are subject to change, jeopardizing the scientific value of this 
rule, this approach is met with serious concerns. Switzerland ob-
ligates all food producers to list involuntary cross- contaminations 
above 1 g allergen per 1 kg food product as “may contain traces of 
…”.5 The German authorities indicate that the threshold depends on 
the respective allergen.6 A similar approach is pursued in Australia 
and New Zealand, where there are no regulations regarding the 
mandatory declaration of unintentionally present allergens.7 The 
VITAL® (Voluntary Incidental Trace Allergen Labelling) program 
is a joint venture of Australia's leading food manufacturers and 
the Australian Food and Grocery Council (AFGC). It provides a 
standardized approach for assessment and declaration of food 
allergen contamination, recommending thresholds based on sci-
entific data that has been processed in a stacked model averaging 
program using a range of statistical calculation models.8 However, 
this leads to modifying the thresholds for each allergen with every 
revision of the program. The aim is to protect the “vast majority 
of people with food allergy” and they state that below the thresh-
olds, only 1% of allergic patients may develop an allergic reaction, 
this reaction however may be severe.9,10 The data processed must 
adhere to high- quality standards and to include only double- blind, 
placebo- controlled, food challenge studies.10- 12 While this is a 
very rigorous approach, some issues may cause bias. One is that 
especially severe allergic reactions are comparatively rare and are 
often published as case reports or case series only. As this form 
of study is considered low- quality evidence in medical science, 
such are not included in the data evaluated by VITAL. Therefore, 
it is likely that the most severe allergic reactions described in the 
literature are not included. Also, fatal reactions are not likely to 
happen while under clinical observation while unintentional inges-
tion of food allergen out of hospital may be more likely to lead to 
death and may be reported only in case reports. In this systematic 
review, an alternative solution for this dilemma is assessed.
Of course, it is acknowledged that some food allergy sufferers 
who have not undergone placebo- controlled tests may not know 
their thresholds but still may have a feeling for it based on previous 
experiences. Therefore, it would be beneficial to know that the al-
lergens included in the food product do not exceed a certain level. 
However, this food contamination level, or concentration, needs to 
be low enough to ensure that no life- threatening or fatal reactions 
have been observed at this level, but also one which can be easily 
measured with existing technologies in the food industry without 
increasing the cost of food production. Therefore, in this systematic 
review, we assess whether a level of 0.5 mg protein/100 g of food 
of allergenic protein would be less than the lowest published ob-
served adverse effect level (LOAEL) for a fatal reaction. As portion 
sizes vary, a maximum portion size of 1 kg of processed food was as-
sumed to exceed any meal and thus giving a sufficient safety margin. 
Therefore, we used 5 mg protein as a threshold in this investigation.
2  |  METHODS
This systematic review was conducted according to the PRISMA 
guidelines for systematic reviews and meta- analyses.13 The review 
was registered on PROSPERO as CRD42018110170.
To find an acceptable threshold levels of allergen contamina-
tion in processed food that would benefit food allergy sufferers and 
would be feasible for the food manufacturers, the first talk was con-
ducted on this topic at the BLL meeting of the allergens specialists 
committee that took place on 8 July 2019 in Berlin, Germany. The 
conference included representatives of the German food industry, 
including food technicians and food manufacturers. The main ques-
tion was which level of food allergen contamination in processed 
food could be detected analytically and reproducibly in quality 
management of food production without increasing the price of the 
food? The level of 5 mg protein was discussed as it is a typical chal-
lenge dose in provocation studies. It was also discussed if voluntary 
labeling would be an option for food production companies. The dis-
cussion resulted in the proposal to use the concentration of 0.5 mg 
of protein per 100 g food as a threshold for voluntary declaration of 
allergen traces in processed food. In this systematic review, it was 
deemed mandatory that even if allergy sufferers would not know 
their personal threshold, that at this level, fatal reactions would have 
never been observed.
2.1  |  Study eligibility
This systematic review includes provocation studies and case reports 
describing life- threatening anaphylactic reactions to one of the 14 main 
allergens in food products were reported. Main food allergens were 
defined in accordance with the European Union's Food Information 
Regulation No. 1169/2011: crustaceans, cereals containing gluten, 
eggs, fish, peanuts, soybean, milk, nuts (namely: almond, hazelnuts, 
walnuts, cashews, pecan nuts, Brazil nuts, pistachio nuts, macadamia, 
or Queensland nuts), celery, mustard, sesame seeds, sulfur dioxide and 
sulfites (sensu stricto and sulfites are not an allergen but known to in-
duce intolerance reactions), lupin, and molluscs (Table 1). Anaphylactic 
reactions were considered life- threatening in case of a fatal outcome, 
potentially fatal outcome without intervention (ie, administration of 
epinephrine, severe dyspnea/asthma, loss of consciousness), positive 
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shock index, and/or hypotension, and/or heart failure. Included studies 
and case reports had to give information on the approximate amount of 
ingested food, for example, “one bite.” Publications had to be written in 
English. Animal studies were excluded.
There is also an abundance of scientific literature that is writ-
ten in Spanish, French, German, and Japanese language for which 
quoted reviews in English exist.
2.2  |  Search strategy and literature screening
MEDLINE and EMBASE electronic databases were searched via 
Ovid from their inception until January 2021. The exact search terms 
are presented in Appendix 1. Titles and abstracts of the retrieved 
references were screened by a team of three reviewers, duplicates 
were eliminated, and potentially relevant references were identi-
fied. A full- text review of the remaining references was performed. 
Studies in which relevance was unclear were discussed by the team 
of reviewers. In addition, the bibliographies of included studies and 
case reports revealed by the search strategy were searched for eligi-
ble articles missed by the search strategy.
2.3  |  Data extraction and analysis
Data regarding the type of ingested food, the approximately in-
gested amount of food, and the type of life- threatening anaphylactic 
reaction were extracted onto a predefined datasheet by the three 
reviewers. In addition, we searched and noted the usual concentra-
tion of allergenic protein for every food product used in the included 
provocation studies or described in the included case studies and 
calculated the amount of ingested allergenic protein. This process 
was verified by a registered dietitian. The studies were analyzed 
regarding the occurrence of life- threatening reactions and the re-
ported amount of food protein provoking the reaction. Finally, the 
data were presented in a table and summarized narratively.
TA B L E  1  Main food allergens according to the European Union's Food Information Regulation No. 1169/2011
Allergen name Including
Amount of protein per 
100 g of food.
Celery Celery root 2 g/100 g
Cereals containing gluten Wheat (such as spelt and khorasan wheat), rye, barley, oats or their 
hybridized strains, and products thereof
Wheat 12 g/100 g
Rye 9 g/100 g
Barley 10 g/100 g
Oats 12 g/100 g
Crustaceans Shrimp 19 g/100 g
Eggs 13 g/100 g
Fish Between 17- 20 g/100 g
Lupin 40 g/100 g
Milk Cow's milk 3 g/100 g
Molluscs Mussel 11 g/100 g
Cuttlefish 16 g/100 g
Mustard 6 g/100 g
Nuts Almonds, hazelnuts, walnuts, cashews, pecan nuts, Brazil nuts, pistachio 
nuts, macadamia or Queensland nuts, and products thereof
Almond 19 g/100 g
Brazil nut 14 g/100 g
Cashew 18 g/100 g
Hazelnut 12 g/100 g
Macadamia 9 g/100 g
Pecan nut 11 g/100 g
Pistachio 18 g/100 g
Walnut 14 g/100 g
Peanut 25 g/100 g
Sesame seeds 21 g/100 g
Soybeans Soybeans 38 g/100 g
Soydrink 4 g/100 ml
Sulfur dioxide and sulfites At concentrations of more than 10 mg/kg or 10 mg/L in terms of the total 
SO2
Not applicable
Sulfites are not an allergen but known to induce intolerance reactions
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2.4  |  Inclusion of authors and discussion with 
stakeholders
An open call for participation was made within the GA2LEN net-
work, which includes EAACI and EFA as members. In addition, 
further patient organizations and other experts in the field of al-
lergology and immunology were actively approached. Some non- 
GA2LEN members accepted the invitation. Participation was denied 
either due to a lack of time or stating a conflict of interest. A Delphi 
process was performed which included all participants. A consensus 
was obtained after two rounds of expert panel evaluations that took 
place on 10 October 2020 and 10 June 2021. The expert panel con-
sisted of German patient organizations, the members of the CODEX 
alimentarius working group, food industry legal advisors, and food 
technologists. Additional data provided by the panel members were 
evaluated and included if eligibility of the study was given.
2.5  |  Risk of bias
The approach that was used in this systematic review has a high level 
of evidence to suggest that at the concentration of 0.5 mg/100 g 
limited to no food fatal reactions will occur; however, there is a 
lower level of evidence regarding the no observed level threshold 
in severely affected allergy sufferers. This is based on the search 
string which will not find these provocation tests in which no life- 
threatening symptoms have occurred.
3  |  RESULTS
The search in MEDLINE and EMBASE via Ovid yielded 3289 ref-
erences, of which we included 90 provocation studies and 88 case 
studies. Figure 1 gives the PRISMA flowchart that presents an over-
view of the search results and study selection.
We analyzed double- blind, placebo- controlled provocation tests 
and case report different minimal threshold levels for different al-
lergens. Some of the other 14 allergens, which must be declared in 
the European Union, such as mustard and molluscs, have not been 
reported as being the trigger of a severe allergic reactions at very 
low levels. Table 2 summarizes the findings from all studies included 
in this analysis that reported severe allergic reactions after ingestion 
of less than 5 mg allergen protein or where the ingested amount was 
unclear. In addition, a summary with all provocation studies and case 
reports included in this analysis is found in the Tables S1 and S2.
In a cohort of food allergic children used by Moneret- Vautrin 
et al.23 for the evaluation of personalized care projects, 2 asthmatic 
reactions resulting from peanut protein amount lower than 5 mg 
have been described. However, the authors state in their paper that 
no fatal reactions were observed. One anaphylactic shock was ob-
served in this study which occurred after ingestion of 965 mg pea-
nut, which amounts to more than 240 mg protein.
Ebrahimi et al.29 report respiratory distress after 3 drops of 
milk- based formula in one study subject who needed to be treated 
with epinephrine. They used BioMeal, Fassbel, Belgium, a formula 
which is no longer available. According to the EU regulations, infant 




















TA B L E  2  Summary of data from provocation studies and case reports in which ingestion of less than 5 mg of allergen protein elicited a severe allergic reaction
Allergen Food product
Nature of life- threatening 
allergic reaction
No. of participants (no. 
experiencing a severe 
reaction)a
Amount of food that 
provoked a severe 
reaction
Amount of allergen protein 
(mg) that provoked a 
severe reaction Study
Cereals No report found for reactions at or below 5 mg
Celery No report found for reactions at or below 5 mg
Crustacean No report found for reactions at or below 5 mg
Egg Mortadella abdominal pain, throat itching, 
vomit, dyspnea
1(1) Mortadella 25 mg 0.0503 Tripodi et al. 200914
Fish Fish Asthma or mild anaphylaxis 1(1) Fish 8 mg 1.36 Lefevre et al. 201615
Lupin Short crust pastry containing lupin 
flour as minor ingredient
asthma 2(1) Small amount Not determinable Bansal et al. 201416
Milk Cow's Milk Asthma or mild anaphylaxis 5 CM <0,05 mg 0.0015 Lefevre et al. 201615
Milk Cow's milk Systemic symptoms Even traces Not determinable Poza- Guedes et al. 
201417
Milk Cow's milk 10(?) Trace amounts Not determinable Paiva et al. 200918
Milk Cow's milk Syncope, hypoxia,
and drop in blood pressure 
treated with epinephrine
1(1) Accidental ingestion of 
trace amounts
Not determinable Lisann et al. 201419
Milk Cow's milk Syncope, hypoxia,
and drop in blood pressure 
treated with epinephrine
1(1) Accidental ingestion of 
trace amounts
Not determinable Lisann et al. 201419
Molluscs No report found for reactions at or below 5 mg
Mustard No report found for reactions at or below 5 mg
Nut Cashews
(Placed in same jar as walnuts)
loss of consciousness Some nuts +febrile 
infection
Not determinable Laliotou et al. 201820
Nut Pinon nut
(SPT extract)
dyspnea One drop cutaneously Not determinable Sindher et al. 201521
Nut Walnut Acute anaphylactic reactions 
including angioedema, 
dyspnea, and cyanosis
1(1) Trace amount Not determinable Noh et al. 200922
Peanut Peanut Asthma 33(1) 15 mg 3.75 Moneret- Vautrin 200123
Peanut Peanut oil Asthma 33(1) 5 mL Not determinable Moneret- Vautrin 200123
Peanut Peanut oil Asthma and/or FEV↓, vomiting 
and/or abdominal pain
103(6) 5 mL Not determinable Morisset et al. 200324
Peanut Peanut oil Asthma 62(14) 5 mL Peanut oil Not determinable Moneret- Vautrin et al. 
199825
    |  9ZUBERBIER Et al.
formula may contain 1.08– 3.6 g protein/100 ml30 provided correct 
preparation. The volume of a “drop” depends on the viscosity of the 
liquid, however, in pharmacy and medicine, a drop is generally de-
fined as being 0.05 mL. The amount ingested may therefore range 
between 1.6 mg and 5.4 mg, although given that the formula is no 
longer on the market, the protein content cannot reliably be veri-
fied. We therefore do not know the amount of milk protein which 
resulted in the described reaction. The same holds true for the re-
action described by Hudes et al28 which reported a “systemic re-
action” to 0.01 ml of soy milk. However, the amount of soy protein 
differs widely between the different brands of soy milk, so the exact 
amount ingested by the patient is not determinable. Furthermore, 
the authors do not describe the systemic reaction in detail and any 
life- threatening potential cannot be determined.
Tripodi et al14 report a case of a 11- year- old with egg allergy de-
veloping dyspnea after ingestion of a mortadella sandwich. They an-
alyzed the mortadella and found the reactive amount being 0.45 mg 
hen's egg, which would mean a protein content of 0.05 mg. They 
did, however, not analyze the other components of the sandwich so 
there is no way to know if this is the real threshold dose.
Dua et al. describe one patient who experienced “throat closure” 
after ingestion of 5 sesame seeds. We weighed different sesame 
seeds on a high precision scale and found an average of 15 mg per 
5 seeds, and could determine that 5 seeds contain approximately 
3.15 mg sesame protein. However, the patient was not treated with 
epinephrine but with oral antihistamines and intravenous hydrocor-
tisone only,27 excluding the likelihood that treating physicians re-
garded it as a truly life- threatening situation.
Both, Morisset et al.24 and Moneret- Vautrin et al.25 described 
potentially life- threatening reactions after the ingestion of sesame 
or peanut oil. As the protein content of oil varies considerably and 
protein amounts have not been measured for the oils used, it is not 
possible to determine an amount.
Hourihane et al.,31 Leung et al.,32 and Lefevre et al.15 list reac-
tions to allergenic amounts <5 mg, but do not describe them further. 
Therefore, those reactions cannot be evaluated further to deter-
mine their life- threatening potential, which is acknowledged to be 
a problem. The same holds true for the following reports where no 
amounts are stated, with one of them being however a clear outlier. 
Robertson et al.26 report on a criminal case where a wife spread pea-
nut dust on her husband's meals. It can be expected that the amount 
was more than 5 mg protein. Poza- Guedes,17 Paiva,18 and Lisann19 
report potentially life- threatening reactions to accidental ingestion 
of trace amounts of cow's milk. As the amounts are not specified, it 
is not possible to determine the allergenic threshold. Laliotou20 and 
Noh22 also state “trace amounts” as triggering an anaphylactic reac-
tion to nut. Again, the missing quantification does create a problem 
and it is possible that a whole nut has been ingested.
The same holds true for the report of Bansal et al.16 where a “small 
amount” of lupin flour in short crust pastry triggered a reaction.
Levin et al33 described the case of a 9- month- old child reacting 
with episodes of asthma, vomiting, and urticaria after ingestion of 
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per liter. Here, it is unclear how much of the formula was adminis-
tered but if it were the typical amount of one bottle containing 150– 
200 ml, this would be most likely more than 5mg, and furthermore, 
it is unclear if the reactions were life- threatening.
Yunginger et al.34 reported 7 fatal cases, 6 of whom had eaten 
at least “one bite” but mostly one cookie or one piece of cake, with-
out further specification of the amount of the relevant allergen. In 
one case of a fish allergic patient, French fries had been consumed, 
which other guests reported tasted of fish. Unfortunately, there is 
no way to estimate in this case, as it is unclear if the reaction was due 
to the sauce offered with the fries.
Azmi et al.35 describe two cases of allergic reactions to vegan ice 
cream containing lupin flour, one of them potentially life- threatening. 
The amount of lupin flour is however not stated and is likely more 
than 5 mg protein since vegan ice cream usually has lupin flour as 
the main ingredient.
4  |  DISCUSSION
4.1  |  Interpretation of results
Remarkably, none of the case reports or provocation tests in a clinical 
setting reported a LOAEL, the lowest ingested dose at which there 
was an observed adverse effect, less than the evaluated threshold 
of 0.5 mg protein/100 g of food, to cause a life- threatening or even 
fatal reaction. The case reports have revealed 8 cases of fatal food 
allergy reactions, however, all at higher levels than 0.5mg/100 g of 
food. Looking at the list of the 14 different allergens which need 
to be declared (celery, cereals containing gluten (such as barley and 
oats), crustaceans (such as prawns, crabs, and lobsters), eggs, fish, 
lupin, milk, molluscs (such as mussels and oysters), mustard, peanuts, 
sesame, soybeans, sulfur dioxide, and sulfites), the following state-
ments can be made:
No severe reactions to trace amounts of molluscs or mustard 
have been reported.
Sulfite is added as an allergen in the list; however, sulfite is in 
reality a cause for pseudoallergic reactions. Life- threatening or fatal 
reactions against sulfites were never reported at all. Still, it is import-
ant to also look at sulfite as severe asthmatic reactions have been 
described in a single report with a threshold of 50 mg.
No severe reactions have ever been reported to low amounts 
of any other allergen that is not listed in the 14 which have to be 
declared according to the EU regulations.
No fatal reactions have ever been reported with levels clearly 
documented below 5mg of protein for any allergen.
In a small subset of patients allergic but not life- threatening reac-
tions can occur at levels below 5mg of protein.
The most important finding of our search is that no fatal allergic 
reactions to food were reported below an estimated amount of 5 mg 
protein.
Any interpretation of the results regarding the reporting bias 
should differentiate case reports of accidental reactions and 
provocation tests. They differ regarding the accuracy of determining 
the amount of allergen ingested and in classifying the reaction as 
“life- threatening.” While case reports are very valuable, as they usu-
ally represent more accurately everyday life situations in which aller-
gic reactions to food occur, the determination of the exact amount 
ingested allergen is difficult and additional cofactors like exercise, 
alcohol, or sleep deprivation may have influenced the manifestation 
or outcome of the reaction.36 Furthermore, case reports depend 
partly on chance because the author has to decide if it was worth 
publishing. An underreporting is therefore possible but less likely for 
fatal cases.
For the second uncertainty, the amount of food ingested, there 
is a potential bias of patients tending to mention smaller amounts 
than truly eaten. In daily practice, a phenomenon often observed 
is that patients feel “guilty” and try to explain with statements such 
as “I hardly took a bite.” Still, as stated in the methods section, the 
overestimation of allergen amounts was chosen generously in case 
reports to avoid false low assumptions leading to inappropriate reas-
surances. Similarly, it should be mentioned that for any ingested nut 
or seed that was reported in the literature, in this review, we con-
sidered the amount of the nut or seed ingested which is definitely 
greater or equal to the amount digested, therefore once again hav-
ing potentially a slight overestimation of the total allergen protein 
amount, this provides a greater safety margin.
Regarding classification accuracy, the courses of actions trig-
gering the label “life- threatening” may be more reliable in the 
out- of- clinic setting. Particularly when looking at the injection of 
epinephrine, which in our methodology categorized the case as po-
tentially fatal, there may be great differences between case reports 
and provocation studies. Many studies have shown that the psycho-
logical barrier of injecting adrenaline is very high in food allergic pa-
tients and their caretakers,37- 39 resulting in a delay or an omission of 
intramuscular epinephrine administration.
On the other hand, handling epinephrine is routine in the clinical 
setting. Since those undergoing a provocation test are monitored 
closely, the first signs of an anaphylactic reaction will generally be 
noticed earlier and trigger counteractive measures, which will in-
fluence the natural course and disguise the severity of the allergic 
response. For example, epinephrine may be administered in cases 
where no life- threatening reaction would develop.
Despite the potential over- estimation in the severity of reactions 
in our study, categorizing all events in which epinephrine was admin-
istered as “life- threatening” increases safety, albeit at the expense 
of accuracy.
In accordance with the findings in this review, a cross- sectional 
study of food allergy prevalence in the population of Berlin by 
Zuberbier et al. revealed that in all open challenge tests, no adverse 
reaction occurred at the level of 5mg of protein.40
However, a study by Ballmer- Weber et al., not included in the 
review as it did not meet all eligibility criteria, found estimated doses 
eliciting reactions in 10% of the study population (ED10), as low as 
1.6 to 10.1 mg of protein for hazelnut, peanut, and celery.41 It should 
be noted that one limitation of this review is the defined search 
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criteria that may have excluded a few other publications that may 
contain further data regarding allergen tolerance thresholds.
This systematic review revealed that 0.5 mg/100 g as a threshold 
value for traces of allergens in processed food is generally a safe 
level for avoiding any allergic reaction to at least 6 of the 14 major 
allergens, even in the unlikely maximum portion size of 1 kg. Even for 
those allergens, a 0.5 mg/100 g threshold is highly likely to be a safe 
level below which fatal allergic reactions will not occur. Depending 
on the portion size, this level is also beneficial for the rare severely 
affected patients. For example, if a patient knows their personal 
threshold level is 2 mg they can still safely eat a portion of 100 g. 
However, the vast majority of all food allergic patients have a much 
higher threshold level for the elicitation of reactions. Very few indi-
viduals will experience symptoms below this level. Our finding of the 
level of 0.5 mg/100 g of food, 100 g of food being a common portion 
size, is in accordance with the FAO- WHO expert group recommen-
dations on allergen thresholds, published on 20 August 2021.120
Based on these results, 5 mg/100 g of food is a concentration 
that can be used in the food industry as the safety level for most 
food allergy sufferers. The advantage of 5 mg/100 g of food is that it 
can be readily detectable for all 14 food allergens with the currently 
existing technology. In addition, avoiding contamination at this level 
should be technically feasible for the food industry as the feasibility 
has been discussed at three different meetings with food technolo-
gists and analytical laboratories. Rare exceptions may occur if ma-
chinery is difficult to clean. For example, pieces of nut in chocolate 
may be a problem, as the allergen is not evenly distributed in the 
food matrix.
There has also been a lot of discussion with different patient 
organizations which would prefer to have legally binding legislation 
regarding the declaration of food allergen contaminants as it remains 
an unmet need. However, we view the voluntary declaration as a 
positive direction that would benefit food allergy sufferers and their 
families.
Such a declaration would not only help all food allergic patients 
who have a known threshold above 5 mg, but it would be also helpful 
to the family of those patients who have anaphylaxis against aller-
gens at levels of <1 mg, to purchase processed foods for the house-
hold, as they would be informed that the food allergic family member 
would not be endangered if products with possibly such low con-
centrations of contaminants would be used within the household. 
The current situation is that often the whole family of severely food 
allergic patients is afraid to buy any processed food at all.
In addition, physicians, dietitians, and nutritionists could better 
advise patients about their risk level in daily practice. This of course 
is mandatory for the exceedingly rare patients described in the lit-
erature who react below 5 mg protein. They should be counseled 
about which processed food, in general, they should avoid.
We propose as a voluntary labeling for the European Union that 
no traces of the 14 main food allergens in a given processed food are 
above 0.5 mg/100 g, together with a warning that traces below this 
level can occur but are likely not harmful. This message can improve 
the situation where manufacturers often state on the packages that 
traces can be contained without stating the amount of the trace, 
that the product has been processed in a facility which also pro-
cessed, for example, peanut products. Both kinds of information are 
more for the sake of the producer to keep away from liability issues 
than for the true benefit of the consuming patient who wants to 
know the exact levels. The 0.5 mg/100 g level, as a clear statement 
on packages, would cover the vast majority of food allergic patients.
Finally, this proposal has been discussed with the food industry 
authorities and a statement that it is regarded as positive has been 
received, found in Appendix 2.
5  |  LIMITATIONS
There are limitations that should be noted in the interpretation of 
the present work. First, due to the defined literature search query, 
there may be some available literature that was not identified in this 
review, and therefore, the data were not taken into consideration. 
An example would be publications on immunotherapy trials where 
low doses of allergen caused reactions, but they were not reported 
as life- threatening or fatal. Due to the large volume of hits obtained 
from the first round of literature screening, the publications were 
screened based on their title and abstract; therefore, it is possible 
that some data included only in the text were overseen. Also, large 
number of studies which were found by our search strategy did not 
report direct relation of the amount of allergen ingested to the ob-
served reaction, therefore, a lot of data addressing food anaphylaxis 
could not be included in our analysis. It should also be taken into 
account that we relate to the amount of allergenic protein ingested. 
If the information was not reported by the investigators, it was cal-
culated based on the usual protein content of the food product used 
in the provocation test or reported in the case report. Despite the 
careful evaluation and supervision of a professional dietitian, it can-
not be ruled out that the amounts given differ from actual amount 
of protein ingested. It should also be mentioned that the screening 
of the data was done by the reviewers separately, data of uncertain 
relevance however was discussed by all three reviewers. Lastly, the 
summary of case reports may give the impression that in most cases 
the dose amount is unknown, suggesting that the information is in-
complete and insufficient. As case reports are a valuable data source 
of real- life situations, it is an unmet need to standardize the investi-
gation and tracking of fatality in food allergy.
6  |  CONCLUSIONS
No fatal reactions have been reported below 5 mg of protein expo-
sure in food allergic patients. The individual eliciting threshold dif-
fers considerably between patients, but the vast majority of patients 
do not react at levels below 5 mg of protein. For these patients, it 
would be helpful to know that contamination with allergens in pro-
cessed food does not exceed this level. Looking at a further safety 
margin, it is therefore proposed that 5mg/kg of contaminating 
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allergen in processed food is not exceeded acknowledging that the 
usual portion size is far lower than 1 kg.
The labeling could read as follows: “this product contains the 
named allergens in the list of ingredients, it may contain traces of 
other contaminants (to be named, e.g. nut) at concentrations less 
than 0.5 mg per 100g of this product” for a voluntary declaration on 
processed food packages.
We further see this only as a first step as legally binding thresh-
olds would be preferred. The authors however feel that realistically 
it would take a long time before this will be implemented on a global 
scale, and in the meantime, the more precise the labeling is the 
better.
Furthermore, we conclude that also this review is only a first step 
in research concentrating on a threshold to avoid fatal reactions, 
more research is needed to identify thresholds for milder symptoms 
of food allergy.
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